Weisenburger DD, Kim H, Rappaport H. Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma. Cancer. 1982;49(7):1429–38.

Article  CAS  PubMed  Google Scholar 

Raffeld M, Jaffe ES. bcl-1, t(ll;14), and mantle cell-derived lymphomas. Blood. 1991;78(2):259–63.

Article  CAS  PubMed  Google Scholar 

Rimokh R, Berger F, Delsol G, Digonnet I, Rouault JP, Tigaud JD, et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood. 1994;83(7):1871–5.

Article  CAS  PubMed  Google Scholar 

Leroux D, Marc’hadour FL, Gressin R, Jacob M-C, Keddari E, Monteil M, et al. Non-Hodgkin’s lymphomas with t(11;14)(q13;q32): a subset of mantle zone/intermediate lymphocytic lymphoma? Br J Haematol.. 1991;77(3):346–53.

Article  CAS  PubMed  Google Scholar 

Williams ME, Meeker TC, Swerdlow SH. Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: analysis with multiple breakpoint probes. Blood. 1991;78(2):493–8.

Article  CAS  PubMed  Google Scholar 

Siebert R, Matthiesen P, Harder S, Zhang Y, Borowski A, Zühlke-Jenisch R, et al. Application of interphase cytogenetics for the detection of t(11;14)(q13;q32) in mantle cell lymphomas. Ann Oncol. 1998;9(5):519–26.

Article  CAS  PubMed  Google Scholar 

Jain P, Wang ML. Mantle cell lymphoma in 2022—a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97(5):638–56.

Article  CAS  PubMed  Google Scholar 

Armitage JO, Longo DL. Mantle-cell lymphoma. N Engl J Med. 2022;386(26):2495–506.

Article  CAS  PubMed  Google Scholar 

Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, et al. Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. J Clin Oncol. 2019;37(6):471–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang KK, Lucas E, Lesher B, Caver T, Tang B. A systematic review of the epidemiology and economic burden of mantle cell lymphoma (MCL). Blood. 2019;134:5831.

Article  Google Scholar 

Albertsson-Lindblad A, Palsdottir T, Smedby KE, Weibull CE, Glimelius I, Jerkeman M. Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen – a real world study on patients diagnosed in Sweden 2007-2017. Haematologica. 2021;107(3):740–3.

Article  PubMed Central  Google Scholar 

Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112(7):2687–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175(3):410–8.

Article  CAS  PubMed  Google Scholar 

Lew TE, Minson A, Dickinson M, Handunnetti SM, Blombery P, Khot A, et al. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. Lancet Haematol. 2023;10(2):e142–e54.

Article  CAS  PubMed  Google Scholar 

Kumar A, Eyre TA, Lewis KL, Thompson MC, Cheah CY. New directions for mantle cell lymphoma in 2022. Am Soc Clin Oncol Educ Book. 2022;42:614–28.

Article  Google Scholar 

Cheminant M, Derrieux C, Touzart A, Schmit S, Grenier A, Trinquand A, et al. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica. 2016;101(3):336–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chovancová J, Bernard T, Stehlíková O, Šálek D, Janíková A, Mayer J, et al. Detection of minimal residual disease in mantle cell lymphoma—establishment of novel eight-color flow cytometry approach. Cytometry B Clin Cytom. 2015;88(2):92–100.

Article  PubMed  Google Scholar 

Minson A, Hamad N, Cheah CY, Tam CS, Blombery P, Westerman DA, et al. Time-limited ibrutinib and tisagenlecleucel is highly effective in the treatment of patients with relapsed or refractory mantle cell lymphoma, including those with TP53 mutated and Btki-refractory disease: first report of the Tarmac study. Blood. 2022;140:181–3.

Article  Google Scholar 

Smith M, Jegede O, Parekh S, Hanson CA, Martin P, Till BG, et al. Minimal residual disease (MRD) assessment in the ECOG1411 randomized phase 2 trial of front-line bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for mantle cell lymphoma (MCL). Blood. 2019;134:751.

Article  Google Scholar 

Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211–23.

Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022;386(26):2482–94.

Article  CAS  PubMed  Google Scholar 

Ferrero S, Grimaldi D, Genuardi E, Drandi D, Zaccaria GM, Alessandria B, et al. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma. Blood. 2022;140(12):1378–89. Update of measurable residual disease and impact of lenalidomide maintenance therapy in mantle cell lymphoma

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoster E, Delfau M-H, Macintyre EA, Jiang L, Stilgenbauer S, Vehling-Kaiser U, et al. Predictive value of minimal residual disease on efficacy of rituximab maintenance in mantle cell lymphoma: results from the European MCL Elderly Trial. Blood. 2022;140(Supplement 1):1304–6.

Article  Google Scholar 

Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood. 2006;107(6):2271–8.

Article  CAS  PubMed  Google Scholar 

Pott C, Hoster E, Delfau-Larue M-H, Beldjord K, Böttcher S, Asnafi V, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115(16):3215–23.

Article  CAS  PubMed  Google Scholar 

Pott C, Macintyre E, Delfau M-H, Weiß A, Schilhabel A, Soehlbrand A, et al. Prediction of relapse by standardized IG-based allel-specific QPCR, DDPCR and amplicon NGS for MRD monitoring in mantle cell lymphoma: a comparative analysis by the EU-MCL network. Hematol Oncol. 2021;39:S2.

Article  Google Scholar 

Callanan MB, Macintyre E, Delfau-Larue M-H, Thieblemont C, Oberic L, Gyan E, et al. Predictive power of early, sequential MRD monitoring in peripheral blood and bone marrow in patients with mantle cell lymphoma following autologous stem cell transplantation with or without rituximab maintenance; final results from the LyMa-MRD Project, conducted on behalf of the Lysa Group. Blood. 2020;136:12–3.

Article  Google Scholar 

Ladetto M, Brüggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia. 2014;28(6):1299–307.

Article  CAS  PubMed  Google Scholar 

Drandi D, Alcantara M, Benmaad I, Söhlbrandt A, Lhermitte L, Zaccaria G, et al. Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the European MCL Network. HemaSphere. 2020;4(2):e347.

Article  PubMed  PubMed Central  Google Scholar 

Le Gouill S, Beldi-Ferchiou A, Alcantara M, Cacheux V, Safar V, Burroni B, et al. Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. Lancet Haematol. 2020;7(11):e798–807.

Article  PubMed  Google Scholar 

Caldwell IR, Ingbritsen M, Yap YZ, Dowling MR, Tiong IS, Westerman DA, et al. Utility of high-throughput sequencing of immunoglobulin genes for MRD in lymphoid malignancy in the context of current immunotherapeutics. Blood. 2022;140:10731–2.

Article  Google Scholar 

Epstein-Peterson ZD, Batlevi CL, Caron P, Dogan A, Drullinsky P, Gerecitano J, et al. Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: phase II, investigator-initiated, single-center study. Blood. 2020;136:11–2.

Article  Google Scholar 

Furqan F, Fenske TS, Longo WL, Johnson B, Hamadani M, Shah NN. MRD status by Clonoseq ® is a poor predictor of long-term outcomes after bispecific LV20.19 CAR T-cell therapy for relapsed, refractory B-cell NHL. Blood. 2022;140:6407–8.

Article  Google Scholar 

Genuardi E, Romano G, Beccuti M, Alessandria B, Mannina D, Califano C, et al. Application of the Euro clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial. Br J Haematol. 2021;194(2):378–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khouja M, Genuardi E, Ferrero S, Alessandria B, Verhagen O, Homburg C, et al. Genotyping and minimal residual disease (MRD) assessment in cfDNA by the euroclonality-NGS DNA capture (EC-NDC) panel in mantle cell lymphoma (MCL). Blood. 2022;140(Supplement 1):3518–20.

Article  Google Scholar 

Lakhotia R, Melani C, Dunleavy K, Pittaluga S, Saba N, Lindenberg L, et al. Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma. Blood Adv. 2022;6(8):2667–80. Use of circulating tumour DNA in mantle cell lymphoma

Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Med. 2014;20(5):548–54.